PReS-FINAL-2064: Effect of Goloimumab a new anti-TNF, in patients with the diagnosis of juvenile idiopathic arthritis

Abstract

Introduction: Golimumab is a fully human monoclonal antibody targeting tumor necrosis factor-alpha (TNF-a), which plays an important role in the pathogenesis of juvenile idiopathic arthritis. Golimumab was approved for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Objectives: To assess the effectivity and safety of Gololimumab in juvenile idiopathic arthritis. Methods: We analysed retrospectively the data of all our patients who have been treated with Golimumab (Simponi) every 28 days sub cutaneously. Results: 18 patients with the diagnosis of juvenile idiopathic arthritis (15 with juvenile enthesitis associated arthritis, 2 with juvenile psoriatic arthritis and 1 with juvenile idiopathic polyarticular arthritis), for a mean time of 13.7 months per patient (4-26 months). 16 patients have been treated with other biologic agents before. In 13 patients Golimumab was started because of disease progression, in 3 because of intolerance to other biologic agents and in 2 because they described severe phobia of injections.Mean number of painful, swollen and limited joints were before and at the end of the treatment period after 13.7 months (4.5/2.39; 1.78/ 0.94; 2.72/2.83). The mean value at baseline after the mean follow up were of the physician global assessment score (2.03/0.84), mean erythrocyte sedimentation rate (8.72 mm/7.41 mm) and mean c-reactive protein (4.36 mg/l/3.97 mg/l). 13 patients developed side effects, one patient developed a severe adverse event (appendicitis with consecutive appendectomy). None of the patients was the drug discontinued because of the side effects. Conclusion: According to this preliminary study in patients with JIA golimumab seems to be a safe and effective treatment. The data of the prospective study is pending.